PRLD
NASD Prelude Therapeutics, Inc.$3.67 ↑ +0.00 (+0.00%) Trading Up from the previous close of $3.67, $0.15 below the day’s high of $3.82
- YTD change
- +26.55%
- vs 20-day SMA
- -19.05%
- vs 200-day SMA
- -5.32%
Price ranges
Price & Performance
-0.01 (-0.27%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 96.2% away from all-time highs of $95.38
- PRLD is up 27% since the beginning of the year
- PRLD is up 155% over the past 12 months
- PRLD is down 32% over the past 1 month
- 8% of all PRLD investors are betting against PRLD
PRLD reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is +151.4%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -8.02%
- vs 8-day SMA
- -9.92%
No alerts for PRLD in the last day.
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
